Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
The MICs of evernimicin at which 90% of Borrelia burgdorferi patient isolates were inhibited ranged from 0.1 to 0.5 microg/ml. Evernimicin was as effective as ceftriaxone against B. burgdorferi in a murine model of experimental Lyme disease. As assessed by culturing the urinary bladders of infected C3H mice, no live Borrelia isolates were recoverable following antibiotic treatment.
Pavia
C S
CS
NYCOM Microbiology and Immunodiagnostic Laboratory of the New York Institute of Technology, Old Westbury, New York 11568, USA. cpavia@iris.nyit.edu
Wormser
G P
GP
Nowakowski
J
J
Cacciapuoti
A
A
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015748:Borrelia burgdorferi Group / Q000187:drug effects*; D002443:Ceftriaxone / Q000494:pharmacology / Q000627:therapeutic use; D002511:Cephalosporins / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D008193:Lyme Disease / Q000188:drug therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D008826:Microbial Sensitivity Tests; D016896:Treatment Outcome
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C001202:evernimicin; D002443:Ceftriaxone